Tuesday, September 11, 2018 10:18:16 AM
Fingers crossed we start to trend up for a change!
https://www.geovax.com/images/180910_Shareholder_Message_FINAL.pdf
http://stockcharts.com/h-sc/ui?s=govx
Don't forget... FAST TRACK Status for vaccine recently!
http://www.wistv.com/story/37919705/geovax-awarded-nih-fast-track-phase-iii-grant-to-advance-lassa-fever-vaccine
Pipeline to die for!
https://www.geovax.com/clinical-pipeline.html
Just won BEST BIOTECH AWARD TOO! GOVS is a REAL CO! Real BOD! REAL REVS coming!
https://globenewswire.com/news-release/2018/04/05/1465727/0/en/GeoVax-Recognized-as-Best-Biotech-at-Vaccine-Industry-Excellence-Awards-during-World-Vaccine-Congress.html
FOX NEWS! (1:37 in)
http://video.foxnews.com/v/4748774457001/?#sp=show-clips
Real BOD!
https://www.geovax.com/corporate-governance/board-of-directors-corporate-governance.html
About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platforms. The Company's HIV vaccine for the clade B epidemic in the Americas and Europe is advancing in human trials conducted by the HIV Vaccine Trials Network. Preclinical programs are focused on preventive vaccines for Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections and cancers. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection and stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit https://www.geovax.com/.
Zacks says, .25 valuation!
https://www.geovax.com/images/GOVX_SCIR-2017-08-22.PDF
Too much good news coming out for GOVX to go unnoticed, imho!
https://finance.yahoo.com/news/geovax-reports-significant-advance-hiv-180000573.html
https://insiderfinancial.com/geovax-labs-inc-otcmktsgovx-just-hit-a-major-hiv-milestone
https://www.geovax.com/clinical-pipeline.html
Significant advances from Duke Medical, Unv. Penn, Alamos! This is HUGE!!!
"This as an important advance in the development of a vaccine with the potential to elicit broadly neutralizing antibody to the CD4 binding site," Dr. Robinson continued. "We intend to push this technology forward for the development of a vaccine for the clade C subtype of HIV that is devastating populations in Africa."
A/S 600M, Float, 105M
http://www.otcmarkets.com/stock/GOVX/profile
Recent GOVX News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/22/2026 04:15:25 AM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 04/17/2026 01:05:12 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 04/17/2026 01:04:57 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 04/17/2026 01:04:42 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 04/17/2026 01:04:30 PM
- Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)] • Edgar (US Regulatory) • 04/17/2026 01:04:15 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/16/2026 08:15:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 09:20:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 07:57:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:15:01 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 08:55:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:21:25 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/17/2026 03:33:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/26/2026 01:23:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 09:31:22 PM
